431
Views
7
CrossRef citations to date
0
Altmetric
Review

No evidence of disease activity in multiple sclerosis patients

, , , , , , , , & show all
Pages 1279-1284 | Received 02 Mar 2016, Accepted 14 Jun 2016, Published online: 07 Jul 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Francois Grand’Maison, Michael Yeung, Sarah A. Morrow, Liesly Lee, Francois Emond, Brian J. Ward, Pierre Laneuville & Robyn Schecter. (2018) Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion 34:8, pages 1419-1430.
Read now

Articles from other publishers (6)

Magdalena Chylińska, Jakub Komendziński, Adam Wyszomirski & Bartosz Karaszewski. (2023) Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis. Multiple Sclerosis International 2023, pages 1-11.
Crossref
C. Mekies, E. Planque, J.P. Delabrousse-Mayoux, P. Giraud & J. Aboab. (2022) Critères d’évaluation d’efficacité d’un traitement de première ligne dans la sclérose en plaques en pratique courante. Pratique Neurologique - FMC 13:2, pages 86-93.
Crossref
Jean-Christophe Brisset, Stephane Kremer, Salem Hannoun, Fabrice Bonneville, Francoise Durand-Dubief, Thomas Tourdias, Christian Barillot, Charles Guttmann, Sandra Vukusic, Vincent Dousset, Francois Cotton, R. Ameli, R. Anxionnat, B. Audoin, A. Attye, E. Bannier, C. Barillot, D. Ben Salem, M.-P. Boncoeur-Martel, G. Bonhomme, F. Bonneville, C. Boutet, J.C. Brisset, F. Cervenanski, B. Claise, O. Commowick, J.-M. Constans, F. Cotton, P. Dardel, H. Desal, V. Dousset, F. Durand-Dubief, J.-C. Ferre, A. Gaultier, E. Gerardin, T. Glattard, S. Grand, T. Grenier, R. Guillevin, C. Guttmann, A. Krainik, S. Kremer, S. Lion, N. Menjot De Champfleur, L. Mondot, O. Outteryck, N. Pyatigorskaya, J.-P. Pruvo, S. Rabaste, J.-P. Ranjeva, J.-A. Roch, J.-C. Sadik, D. Sappey-Marinier, J. Savatovsky, B. Stankoff, J.-Y. Tanguy, A. Tourbah, T. Tourdias, B. Brochet, R. Casey, F. Cotton, J. De Sèze, P. Douek, F. Guillemin, D. Laplaud, C. Lebrun-Frenay, L. Mansuy, T. Moreau, J. Olaiz, J. Pelletier, C. Rigaud-Bully, B. Stankoff, S. Vukusic, M. Debouverie, G. Edan, J. Ciron, C. Lubetzki, P. Vermersch, P. Labauge, G. Defer, E. Berger, P. Clavelou, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Créange, J.-P. Camdessanché, S. Bakchine, A. Maurousset, I. Patry, T. De Broucker, C. Pottier, J.-P. Neau, C. Labeyrie & C. Nifle. (2020) New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. Journal of Neuroradiology 47:4, pages 250-258.
Crossref
Syed A. Rizvi, Joshua A. Stone, Saima T. Chaudhry, Nichola Haddad, Brian Wong & Jennifer O. Grimes. 2020. Clinical Neuroimmunology. Clinical Neuroimmunology 159 177 .
Bilgesu Genc, Hemdem Rodi Bozan, Sermin Genc & Kursad Genc. 2019. Tissue Engineering and Regenerative Medicine. Tissue Engineering and Regenerative Medicine 145 174 .
Garrick D. Talmage, Oscar J. M. Coppes, Adil Javed & Jacqueline Bernard. (2017) Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLOS ONE 12:4, pages e0173299.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.